22,650€
2,51%
Echtzeit-Aktienkurs PROVENTION BIO DL-,0001
Bid:
Ask:
Echtzeit-Chart der PROVENTION BIO DL-,0001 Aktie
Börsenkurse PROVENTION BIO DL-,0001
Fundamentaldaten der PROVENTION BIO DL-,0001 Aktie
Aktuelle Geschäftsentwicklung
Sie benötigen die TraderFox Börsensoftware, um die aktuelle Geschäftsentwicklung einsehen zu können.
Income Statement: 10-Year-Summary
Datum | Umsatz | EBIT | Gewinn | EPS | Dividende | KGV | KUV |
---|---|---|---|---|---|---|---|
2022 [USD] | 12,90 Mio. | -126,96 Mio. | -113,57 Mio. | -1,52 | - | - | 153,99 |
2021 [USD] | 1,40 Mio. | -115,43 Mio. | -114,43 Mio. | -1,81 | - | - | 1028,99 |
2020 [USD] | - | -99,10 Mio. | -98,58 Mio. | -1,88 | - | - | - |
2019 [USD] | - | -43,29 Mio. | -43,29 Mio. | -1,06 | - | - | - |
2018 [USD] | - | -26,67 Mio. | -26,48 Mio. | -1,19 | - | - | - |
2017 [USD] | - | -9,13 Mio. | -9,13 Mio. | -0,26 | - | - | - |
2016 [USD] | - | -0,16 Mio. | -0,16 Mio. | 0,00 | - | - | - |
Die Multiples wie die KGVs werden mit der Bilanzwährung und dem Kurs des ausgewählten Börsenplatzes berechnet. Wählen Sie den Börsenplatz mit der Bilanzwährung aus, damit die Multiples korrekt sind. Die fundamentalen Daten werden von Facunda geliefert; Multiples werden mit dem aktuellen Kurs berechnet. |
Profil der PROVENTION BIO DL-,0001 Aktie
Provention Bio is a clinical-stage biopharmaceutical company dedicated to sourcing, developing, and commercializing novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated disease. Their predict and prevent model is focused on developing novel therapeutic approaches that intervene before the target disease begins, re-appears, or progresses. Provention Bio offers the potential to reduce the high morbidity, mortality, patient suffering, and escalating costs of chronic autoimmune and inflammatory diseases, such as type 1 diabetes (T1D), Crohn’s disease, ulcerative colitis, and emerging viral infections. They believe Provention’s business model, coupled with its expertise in translational medicine, immunology, and the design and execution of rapid go/no-go clinical trials, will enable them to in-license and efficiently partner both early-stage development assets and more advanced clinical-stage opportunities.